Dr Triparna Sen speaks to ecancer about lineage plasticity in lung cancer and its biological and therapeutic implications.
Initially, Dr Sen explains the background of this study. Transformation of lung adenocarcinoma to a more aggressive, neuroendocrine derivative, small cell lung cancer, is a well-known mechanism of lineage plasticity and resistance to targeted therapies in lung cancer.
This study, reports the first comprehensive multi-omic (genomic, transcriptomic, epigenomic, and proteomic) characterisation of lung adenocarcinoma to small cell lung cancer transformation in a large cohort of clinical samples.
Dr Sen provides novel insights into molecular drivers and potential therapeutic vulnerabilities of this neuroendocrine transformation in lung cancer. In the end, she discusses the impact of these results on the future of lung cancer